Ganirelix
Overview
A synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells. Ganirelix rapidly suppresses LH secretion within hours of administration, preventing premature ovulation during assisted reproductive technology (ART) cycles.
Mechanism of Action
Its mechanism provides immediate suppression without the flare phase associated with GnRH agonists.
Research Summary & Key Findings
FDA-approved for prevention of premature LH surges during controlled ovarian hyperstimulation. Clinical trials demonstrated equivalent pregnancy rates to GnRH agonist protocols with significantly reduced OHSS risk and shorter stimulation duration. The fixed-start protocol (day 5-6 of stimulation) offers simplicity and predictability in IVF cycle management.
Clinical Status
Ganirelix has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Ganirelix"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Ganirelix"
Registered interventional and observational studies, including status and phase.
- PubChem — "Ganirelix"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Reproductive
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory ph...
View detailsGoserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug r...
View detailsCetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose...
View detailsCarbetocin
In Clinical TrialsA long-acting synthetic analog of oxytocin with a modified disulfide bridge that confers resistance to enzymatic degrada...
View detailsStart Your Consultation
Get an AI-proposed Ganirelix protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Ganirelix.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.